Summary of the Key Points
This news report focuses on a scandal involving hemophilia patients who have become involved in insurance fraud due to a "free medication + rebate" scheme. The cost of treating hemophilia is extremely high, amounting to 500,000 yuan per year. Domestic pharmaceutical companies have enabled patients to achieve "zero out-of-pocket costs" through a combination of medical insurance reimbursement and charitable subsidies/rebates. However, this approach exploits loopholes in the medical insurance regulations—adult preventive medication is not covered by insurance—resulting in the misuse of insurance funds. After fraud cases emerged in regions such as Zhejiang, many places have tightened their medication policies. Patients are now worried about facing criminal charges, and this has exposed the deep-seated contradictions between efforts to control medical insurance costs, pharmaceutical companies' sales strategies, and patients' urgent need for life-saving treatments.
1. "Free medication plus cash back": Why do patients cross the line of insurance fraud?
Hemophilia patients spend 500,000 yuan annually on medication. Even after reimbursement, they still have to pay a portion out of pocket. Domestic pharmaceutical companies, such as Shenzhou Cell's Anjiayin, have taken this "zero-out-of-pocket" concept to the extreme: medical insurance covers most of the cost, and the companies make up for the difference through "charitable assistance" and financial subsidies, even offering a 4% rebate (for example, in the Zhejiang case, a patient received 35,000 yuan in rebates over two years). For patients, this seems like a win-win situation where they don't spend any money and even get a profit. The problem is that medical insurance regulations specify that recombinant factor VIII can only be reimbursed for children or when used during acute bleeding episodes; adult preventive medication (used to prevent bleeding through regular injections) is not covered—this practice constitutes the misuse of insurance funds and is considered insurance fraud.
2. After the fraud cases: Patients face difficulties accessing medication and fear of imprisonment
Following the Zhejiang case, many regions have tightened their policies:
- Stricter regulations: Places like Anhui and Inner Mongolia now require that medication be prescribed only when a patient is experiencing bleeding and appears in person at the hospital. Previously, patients could get 20–30 bottles of medication; now, they can only get 10 bottles per month.
- Patient panic: Many patients who were part of the "free medication" scheme are worried about being sentenced to probation or having a criminal record, similar to the 24-year-old patient in the Zhejiang case.
- Backtracking of usage records: Some provinces have even reviewed medication records from the past five years, and since Anjiayin was launched in 2021, it falls within this time frame, causing additional concern among patients.
3. The root of the contradiction: Medication that insurance does not cover is essential for patient survival
The restrictions on medical insurance have historical reasons. In the past, imported recombinant factors were expensive, so insurance only covered them during acute bleeding episodes to save costs. However, with the reduction in prices of domestic drugs, preventive medication can help reduce bleeding and improve quality of life (for example, by reducing the frequency of spontaneous bleeding from 2–3 times a week). Yet, medical insurance guidelines have not been updated accordingly. Pharmaceutical companies use rebates to encourage patients to use drugs that are not supposed to be covered by insurance, leading to a significant consumption of insurance funds (Anjiayin accounted for 22% of national rare disease insurance expenditures in 2024), which ultimately triggered regulatory action.
4. Who is to blame? Pharmaceutical companies, distributors, doctors, or patients?
- Pharmaceutical companies: They often blame the behavior of individual distributors, but their sales strategies (high rebates, frequent patient education) are approved by the companies, and sales have skyrocketed (from 134 million yuan in 2018 to 1.89 billion yuan in 2021), making them the biggest beneficiaries.
- Distributors: They have become the scapegoats; in the Zhejiang case, distributors were accused of fraud involving nearly 100 million yuan and face severe penalties, but they are merely executors of the companies' policies.
- Doctors: If they accept bribes or prescribe excessive amounts of medication, they may be considered accomplices; if they prescribe preventive drugs according to medical guidelines (although it may be against regulations), they could also face investigation.
- Patients: Those who receive rebates may be charged as accomplices in fraud, even if they were unaware of the scheme and only benefited financially.
5. Where is the solution? Ensuring that life-saving medication is truly accessible to patients
The key to solving this issue is to include adult preventive medication in the medical insurance coverage:
- This would allow patients to use the medication legally without the risk of fraud.
- Medical insurance could negotiate lower prices and regulate expenditures (for example, by requiring companies to waive rebates and pass the savings directly to the insurance system rather than individual patients).
- Doctors could prescribe medication according to medical guidelines without having to struggle between providing necessary treatment and adhering to regulations.
This path is difficult, but it would benefit all parties involved—after all, the purpose of life-saving medication is to help patients live, not to drag them into legal disputes.